2021
DOI: 10.3389/fimmu.2021.694118
|View full text |Cite
|
Sign up to set email alerts
|

Hematopoietic Stem Cells in Type 1 Diabetes

Abstract: Despite the increasing knowledge of pathophysiological mechanisms underlying the onset of type 1 diabetes (T1D), the quest for therapeutic options capable of delaying/reverting the diseases is still ongoing. Among all strategies currently tested in T1D, the use of hematopoietic stem cell (HSC)-based approaches and of teplizumab, showed the most encouraging results. Few clinical trials have already demonstrated the beneficial effects of HSCs in T1D, while the durability of the effect is yet to be established. I… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(4 citation statements)
references
References 44 publications
0
4
0
Order By: Relevance
“…Immunomodulatory activity is the most important ability of HSCs in patients with T1DM. HSCs can inhibit the occurrence of T1DM (76)(77)(78). Patients with recent-onset T1DM have been triumphantly reverted to euglycemia by autologous hematopoietic stem and progenitor cell transplantation (AHSCT), and modulation of autologous hematopoietic stem and progenitor cells (HSPCs) with prostaglandins (PGs) in vitro enhances their immunoregulatory properties through increasing the expression of the immune checkpoint-signaling molecule PD-L1 (79).…”
Section: Immunomodulatory Ability Of Hscsmentioning
confidence: 99%
See 1 more Smart Citation
“…Immunomodulatory activity is the most important ability of HSCs in patients with T1DM. HSCs can inhibit the occurrence of T1DM (76)(77)(78). Patients with recent-onset T1DM have been triumphantly reverted to euglycemia by autologous hematopoietic stem and progenitor cell transplantation (AHSCT), and modulation of autologous hematopoietic stem and progenitor cells (HSPCs) with prostaglandins (PGs) in vitro enhances their immunoregulatory properties through increasing the expression of the immune checkpoint-signaling molecule PD-L1 (79).…”
Section: Immunomodulatory Ability Of Hscsmentioning
confidence: 99%
“…The genetically modified HSCs were used to overcome the disadvantage. Ex-vivo genetic manipulation of NOD HSCs to encode proinsulin and transgenically target MHC class II could successfully prevent T1DM onset (78,82). The increased CXCL12 (SDF-1) level in bone marrow-derived HSCs of NOD mice is considered to change the transport of HSCs and peripheral dendritic cells, which is conducive to the occurrence of T1DM (78, 83).…”
Section: Immunomodulatory Ability Of Hscsmentioning
confidence: 99%
“… 104 Hematopoietic stem cells, initially implemented in the hematological field, were proposed for the treatment of T1D, systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. 105 Immunosuppression followed by autologous hematopoietic stem cell transplantation can restore insulin production in most patients with recent onset of T1D. 106 Although a wide heterogeneity regarding inclusion criteria, studies with autologous hematopoietic stem cells differ for therapeutic regimens of immunosuppression, stem cell mobilization protocol, conditioning regimen, and the number of autologous hematopoietic stem cells infused; an optimal β-cells reserve and low levels of autoantibodies seem to be associated with an effective response.…”
Section: Stem Cells Derived Pancreatic β-Cellsmentioning
confidence: 99%
“…Stem cell-derived isletlike cell transplantation restores insulin independence and normal blood glucose levels in diabetes patients, 6 but development of functional cells that fully replicate all aspects of endogenous β cells remains elusive. 7 Additionally, the potent immunomodulatory properties of mesenchymal stem cells and haematopoietic stem cells also offer novel promising treatment approaches for diabetes patients [8][9][10][11][12] and produce beneficial effects in glycaemic control, but their effectiveness requires continual verification. 13 Human amniotic epithelial cells (hAECs) are embryonic stem cell-like cells with immunomodulatory ability, which can be conveniently sourced.…”
Section: Introductionmentioning
confidence: 99%